2023
Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms
Koh M, Boussi L, Han J, Peng L, Sorial M, Eche-Ugwu I, Miranda E, Chiattone C, Stuver R, Horwitz S, Turizo M, McCabe S, Merrill M, Jacobsen E, Kim J, Kim Y, Cho J, Eipe T, Shet T, Jain H, Sengar M, Singh S, Gabler J, Koh M, Van Der Weyden C, Prince M, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al Mansour M, Ford J, Manni M, Federico M, O'Connor O, Cabrera M, Shen C, Marchi E, Shah D, Jain S. Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms. Blood 2023, 142: 1703. DOI: 10.1182/blood-2023-185881.Peer-Reviewed Original ResearchSuperior overall survivalCytotoxic chemotherapyOverall survivalNK-cell neoplasmsBrentuximab vedotinPTCL-NOSMultivariate CoxSingle agentALK- ALCLSmall molecule inhibitorsComparable OSGlobal cohortLargest global cohortClinical trialsT cellsConcordance indexMultivariate Cox regression modelSecond-line therapyPrimary refractory patientsIndependent prognostic effectCox regression modelMolecule inhibitorsReal-world evidenceEpigenetic modifiersMature T cellsCost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapyQuality-adjusted life yearsIncremental cost-effectiveness ratioCAR T cellsChimeric antigen receptor T-cell therapySOC therapyFollicular lymphomaT cellsLife yearsR FLRefractory follicular lymphomaT cell strategiesThird-line settingLines of therapyIncremental clinical benefitUS payer perspectiveCost-effectiveness ratioTherapy remissionUnselected patientsCare therapyClinical benefitClinical trialsTreatment strategiesPayer perspective
2022
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis
Shafagati N, Koh M, Boussi L, Park H, Stuver R, Bain P, Foss FM, Shen C, Jain S. Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis. Blood Advances 2022, 6: 4740-4762. PMID: 35816645, PMCID: PMC9631658, DOI: 10.1182/bloodadvances.2022007425.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaOverall response rateR Peripheral T Cell LymphomaCombination chemotherapyT-cell lymphomaSingle agentComparative efficacyRefractory T-cell lymphomaPhase ISingle-agent strategyPhase II trialPlatinum-based regimensPhase III trialsPhase I trialOptimal treatment strategyNovel single agentsRandom-effects modelSignificant subgroup differencesII trialIII trialsI trialHistological subtypesTreatment paradigmClinical trialsDrug classesPrimary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022, 140: 419-437. PMID: 34758074, PMCID: PMC9353153, DOI: 10.1182/blood.2021012057.Peer-Reviewed Original ResearchConceptsPrimary cutaneous lymphomasNon-Hodgkin lymphomaCutaneous lymphomasMycosis fungoides/Sézary syndromeCutaneous Lymphoma Task ForceInvestigator-initiated trialPotential prognostic factorsNumber of patientsClinical trial guidelinesClinical trial designExtracutaneous diseaseSézary syndromePrognostic factorsTreatment of cancerTrials guidelinesClinical trialsComparative efficacyTrial designNumber of subtypesEuropean OrganizationNew treatmentsLymphomaResponse criteriaTherapeutic agentsStudy design
2021
Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis
Shafagati N, Stuver R, Boussi L, Koh M, Park A, Bain P, Foss F, Shen C, Jain S. Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis. Blood 2021, 138: 1431. DOI: 10.1182/blood-2021-150315.Peer-Reviewed Original ResearchOverall response rateT-cell lymphomaHistological subtypesNovel single agentsSingle agentHistone deacetylase inhibitorsConventional chemotherapyResponse rateCentral RegisterPartial responsePTCL-NOSClinical trialsChemotherapy agentsComparable overall response ratesGeneric inverse variance methodCutaneous T-cell lymphomaPhase IParticular histological subtypeSpeakers bureauCochrane Central RegisterProgression-free survivalMature T-cell lymphomasPI3K/Akt/mTORDuration of responseInverse variance methodResponse to Extracorporeal Photopheresis in Patients with Cutaneous T-Cell Lymphoma: A Retrospective Medical Chart Review
Girardi M, Johnson A, Carlson K, Huang X, Corman S, Edmundson P, Kale H, Rusibamayila N, Foss F. Response to Extracorporeal Photopheresis in Patients with Cutaneous T-Cell Lymphoma: A Retrospective Medical Chart Review. Blood 2021, 138: 1405. DOI: 10.1182/blood-2021-151116.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaBody surface areaNew skin lesionsHalf of patientsExtracorporeal photopheresisT-cell lymphomaMallinckrodt PharmaceuticalsECP initiationClinical outcomesClinical trialsSkin lesionsInterim analysisRetrospective medical chart review studyResponse rateClinical Global Impressions-Improvement scoreDiagnosis of CTCLTreatment of CTCLClinical sitesStructured case report formRetrospective medical chart reviewMedical chart review studyReal-world clinical practiceSpeakers bureauStage IV diseaseAdvanced stage disease
2019
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas
Foss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko Y, Montoto S, Chiattone C, Moskowitz A, Spina M, Cesaretti M, Biasoli I, Federico M. Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. American Journal Of Hematology 2019, 95: 151-155. PMID: 31709579, PMCID: PMC8025136, DOI: 10.1002/ajh.25674.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overDisease-Free SurvivalEnteropathy-Associated T-Cell LymphomaFemaleHematopoietic Stem Cell TransplantationHumansIncidenceLymphoma, T-Cell, PeripheralMaleMiddle AgedNeoplasm ProteinsReceptors, Antigen, T-Cell, gamma-deltaSurvival RateTransplantation, AutologousConceptsHepatosplenic T-cell lymphomaT-cell lymphomaEnteropathy-Associated T-Cell LymphomaGamma-delta T-cell lymphomaT-cell ProjectStem cell transplantationCell lymphomaRare subtypeFirst remissionTreatment patternsCell transplantationAutologous stem cell transplantationAllogeneic stem cell transplantationFirst-line therapyLarge prospective trialsProgression-free survivalCells projectRare T cellsNovel treatment approachesFree survivalLine therapyOverall survivalProspective trialAnthracycline regimensClinical trials
2015
The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project
Bellei M, Nabhan C, Pesce EA, Conte L, Vose JM, Foss F, Federico M. The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project. Current Hematologic Malignancy Reports 2015, 10: 448-455. PMID: 26449717, DOI: 10.1007/s11899-015-0291-0.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell ProjectLymphoma RegistryCell lymphomaManagement of PTCLFuture clinical trialsOptimal therapeutic strategyT-cell lymphomaB-cell lymphomaPoor prognosisLymphoma treatmentLarge registriesClinical trialsLymphoid malignanciesTherapeutic strategiesNew agentsRegistryHeterogeneous groupPrognosisLymphoma
2011
Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma
Foss FM. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. Expert Opinion On Drug Metabolism & Toxicology 2011, 7: 1141-1152. PMID: 21726160, DOI: 10.1517/17425255.2011.595404.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaRefractory peripheral T-cell lymphomaPhase I/II trialEarly phase I/II trialsCutaneous T-cell lymphomaAggressive T-cell lymphomaT-cell lymphoma subtypesFrequent adverse eventsStem cell transplantationT-cell neoplasmsII trialAdverse eventsMost patientsHodgkin's diseasePreclinical findingsClinical efficacyLymphoma trialsPoor outcomeConventional therapyHodgkin's lymphomaReversible thrombocytopeniaHematologic malignanciesClinical trialsClinical studiesPeripheral T-cell lymphoma
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011, 117: 6756-6767. PMID: 21493798, DOI: 10.1182/blood-2010-05-231548.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaStandard chemotherapeutic regimensBest treatment strategyMore effective therapiesHistone deacetylase inhibitorsWorld Health OrganizationAbundance of drugsAggressive diseaseChemotherapeutic regimensPoor outcomeTreatment optionsClinical trialsEffective therapyTreatment strategiesTherapeutic approachesPrognostic issuesDeacetylase inhibitorsLymphoma classificationMonoclonal antibodiesGene expression profilingHeterogeneous groupHealth OrganizationProteasome inhibitorsDisease biologyRelapsed and refractory PTCL—into the therapeutic abyss
Foss F. Relapsed and refractory PTCL—into the therapeutic abyss. Nature Reviews Clinical Oncology 2011, 8: 321-322. PMID: 21468128, DOI: 10.1038/nrclinonc.2011.51.Peer-Reviewed Original Research
2010
Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)
Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal Of The American Academy Of Dermatology 2010, 64: 352-404. PMID: 21145619, DOI: 10.1016/j.jaad.2010.08.037.Peer-Reviewed Original ResearchMeSH KeywordsAlkylating AgentsAntibodies, MonoclonalAntineoplastic AgentsClinical Trials as TopicCombined Modality TherapyDrug Therapy, CombinationEvidence-Based MedicineHistone Deacetylase InhibitorsHumansImmunologic FactorsMethotrexateMycosis FungoidesQuality of LifeRetinoidsSezary SyndromeSkin NeoplasmsConceptsUnited States Cutaneous Lymphoma ConsortiumSézary syndromeTherapeutic optionsTreatment of SSPreventive services guidelinesCurrent treatment optionsEvidence-based medicineMechanism of actionAdjuvant treatmentMycosis fungoidesPoor prognosisCombination therapyTreatment optionsClinical trialsClinical carePromising treatmentSpecific efficacyStandardized reviewOverall efficacyStandardized criteriaTherapyService guidelinesAdverse effectsImmunopathogenesisTreatmentRole of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma
Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Management And Research 2010, Volume 2: 53-59. PMID: 21188096, PMCID: PMC3004568, DOI: 10.2147/cmar.s5009.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaTreatment of patientsT-cell lymphomaDenileukin diftitoxFusion protein toxinsT cellsCytocidal agentsRare lymphoproliferative disorderPivotal clinical trialsMalignant T cellsBiological response modifiersQuality of lifeMechanism of actionCD25 subunitCommon toxicitiesProgressive lymphomaLymphoproliferative disordersClinical trialsResponse modifiersIL2 receptorTraditional chemotherapyDiftitoxB cellsFDA approval
2004
Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome
Foss FM. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. Best Practice & Research Clinical Haematology 2004, 17: 573-584. PMID: 15494295, DOI: 10.1016/j.beha.2004.08.009.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeAnti-vascular endothelial growth factorChemotherapeutic agentsAllogeneic bone marrow transplantationReceptor tyrosine kinase inhibitorsGrowth factorTransplant conditioning regimensBone marrow transplantationTyrosine kinase inhibitorsClonal hematopoietic disordersEndothelial growth factorNovel chemotherapeutic agentsMatrix metalloproteinase inhibitorsFarnesyl transferase inhibitorsIntensive chemotherapyConditioning regimensSupportive careFavorable cytogeneticsPrognostic factorsAntimetabolite therapyMarrow transplantationMDS patientsTreatment paradigmClinical trialsProtein kinase C inhibitor
2003
Novel agents for cutaneous T-cell lymphoma
Kuzel TM, Junghans R, Foss FM. Novel agents for cutaneous T-cell lymphoma. Hematology/Oncology Clinics Of North America 2003, 17: 1459-1466. PMID: 14710896, DOI: 10.1016/s0889-8588(03)00112-6.Peer-Reviewed Original Research
2002
Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene
Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM. Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. Leukemia Research 2002, 26: 1077-1083. PMID: 12443879, DOI: 10.1016/s0145-2126(02)00059-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArginineButyratesCell SurvivalCyclic AMPDiphtheria ToxinDose-Response Relationship, DrugDrug SynergismHumansInterleukin-2Interleukin-2 Receptor beta SubunitLeukemiaLymphomaReceptors, InterleukinReceptors, Interleukin-2Recombinant Fusion ProteinsResponse ElementsSecond Messenger SystemsUp-RegulationConceptsCutaneous T-cell lymphomaIL-2R expressionNon-Hodgkin lymphomaArginine butyrateIL-2RLow affinity IL-2RHistone deacetylaseDirect growth-inhibitory effectB-cell non-Hodgkin lymphomaHigh-affinity IL-2 receptorLeukemia cellsCAMP response elementT-cell lymphomaIL-2 receptorNative diphtheria toxinGrowth inhibitory effectsClinical trialsP75 subunitAchievable concentrationsResponse rateVitro dataDAB389IL-2Interleukin-2 geneTumor cellsLymphoma cells